Here we performed a systematic search to identify breast-cancer-specific small noncoding RNAs, which we have collectively termed orphan noncoding RNAs (oncRNAs). We subsequently discovered that one of these oncRNAs, which originates from the 3′ end of TERC, acts as a regulator of gene expression and is a robust promoter of breast cancer metastasis. This oncRNA, which we have named T3p, exerts its prometastatic effects by acting as an inhibitor of RISC complex activity and increasing the expression of the prometastatic genes NUPR1 and PANX2. Furthermore, we have shown that oncRNAs are present in cancer-cell-derived extracellular vesicles, raising the possibility that these circulating oncRNAs may also have a role in non-cell autonomous disease pathogenesis. Additionally, these circulating oncRNAs present a novel avenue for cancer fingerprinting using liquid biopsies.
T he widespread reprogramming of the gene expression landscape is a hallmark of cancer development. Therefore, the systematic identification of regulatory pathways that drive pathologic gene expression patterns is a crucial step towards understanding and treating cancer. Many regulatory mechanisms have been implicated in the oncogenic expression of genes involved in tumor progression. In addition to the transcriptional networks that underlie metastasis, post-transcriptional regulatory pathways have also emerged as major regulators of this process. MicroRNAs (miRNAs), a subclass of small RNAs (smRNAs) involved in gene silencing, were among the first post-transcriptional regulators to be functionally implicated in the progression of breast cancer 1 . RNA-binding proteins (RBPs) are also critical regulators of gene expression, and several specific RBPs have been shown to affect oncogenesis and cancer progression [2] [3] [4] [5] . Recently, we have shown that tRNAs 6 and tRNA fragments 7 , two other classes of small noncoding RNAs, also have important roles in breast cancer metastasis.
Despite the diversity of known regulatory mechanisms involved in cancers, these mechanisms share the characteristic of deregulating existing cellular pathways. To activate oncogenic processes and downregulate tumor-suppressive pathways, cancer cells use many strategies, including somatic mutations (for example, in KRAS 8 ), genetic amplifications/deletions (for example, in EGFR 9 ), gene fusions (for example, BCR-ABL 10 ) and epigenetic modifications (for example, promoter hypermethylation 11 ). Although these oncogenic strategies rely on the genetic or epigenetic modulation of existing regulatory programs, there is an unexplored possibility that cancer cells may be capable of engineering regulatory pathways that function at the RNA or protein level to drive tumorigenesis by enforcing pro-oncogenic gene expression patterns. This idea is further reinforced by the current understanding of cancer progression as an evolutionary and ecological process 12 . In this study, we investigated whether tumors can evolve this type of novel regulatory program that drives cancer progression. We hypothesized that new regulatory pathways could emerge through a two-step evolutionary process: the appearance of a pool of sufficiently abundant and diverse macromolecules with regulatory potential and the subsequent adoption of these molecules as functional neoregulators of gene expression patterns. Because noncoding RNAs rely on their base-pairing capacity and interactions with RBPs to carry out their regulatory functions, it follows that novel cancer-cell-specific RNA species have this same potential. On the basis of this broad regulatory potential, we focused on cancer-cell-specific small noncoding RNAs as a possible source of tumor-evolved regulators capable of modulating disease-relevant pathways and processes.
To search for smRNAs that are expressed in breast cancer cells and are undetectable in normal breast tissue, we implemented an unbiased approach, combining small-RNA sequencing (smRNAseq) of cancer cell lines and patient-derived xenograft (PDX) models, as well as integrating the analysis of existing clinical breast cancer datasets. We discovered and annotated 201 previously unknown smRNAs that were expressed in breast cancer cells and not in mammary epithelial cells. We call these RNAs 'orphan' noncoding RNAs (oncRNAs) to highlight their cancer-specific biogenesis. To assess whether any members of this class had a direct role in breast cancer progression, we compared the expression of oncRNAs in poorly and highly metastatic cells. We successfully identified, characterized and validated the cancer-relevant function of one such oncRNA that is generated from the 3′ end of TERC (the RNA component of telomerase). This oncRNA, which we have named T3p, promotes breast cancer metastasis by acting as a decoy for the RISC complex in breast cancer cells. Furthermore, we demonstrated that a number of oncRNAs, including T3p, can be detected in extracellular vesicles originating from cancer cells, raising the possibility that they may have an emergent role in educating nontumor cells. Clinically, given their absence in normal cells, extracellular oncRNAs could serve as a specific digital fingerprint of the underlying cancer cells.
Results
A systematic search for orphan small noncoding RNAs in breast cancer. We first sought to determine whether a set of smRNAs exists that is only expressed in cancer cells and that could provide a pool of potential regulators. We reasoned that such oncRNAs would only be detectable in cancer cell lines and not in normal cells. To test this hypothesis, we performed smRNA-seq on eight human breast cancer cell lines (representing all major breast cancer subtypes), as well as human mammary epithelial cells (HMECs) as a nontransformed reference sample. We identified 437 unannotated smRNAs that were detected above a significance threshold across all breast cancer lines and were not detected in HMEC samples ( Fig. 1a ).
To further narrow our search, we performed a similar analysis on smRNA-seq data obtained from The Cancer Genome Atlas (TCGA) that consisted of smRNA expression profiles across roughly 200 normal tissue samples and 1,000 breast cancer biopsies. The highly significant overlap between these two independent analyses revealed a high-confidence set of 201 oncRNAs ( Fig. 1b and Supplementary  Fig. 1a ). To independently validate this oncRNA set, we generated a dataset of smRNA profiles from 10 samples from breast cancer PDX models and four normal epithelial unmatched samples. As shown in Fig. 1c , these oncRNAs are mostly absent from normal samples, yet are frequently detected in this set of PDX models. By summing the expression of all 201 oncRNAs across every sample, we derived a simple classification rule that perfectly assigns the normal and PDX profiles to their correct group ( Supplementary Fig. 1b ). Together, these findings establish the existence of a pool of oncRNAs, the expression of which is strongly associated with breast cancer and is mostly undetected in normal tissue.
Identification of T3p
, an oncRNA associated with breast cancer progression. oncRNAs provide a cancer-cell-specific pool of RNA species. However, the potential oncogenic function of these RNAs remained unknown. To address this question, we performed a series of analyses to identify those oncRNAs that are strongly associated with breast cancer progression. First, in addition to the cell lines assessed in Fig. 1 , we profiled two highly metastatic breast cancer cell lines that were previously selected in vivo in immunocompromised mice for higher metastatic capacity to the lung 1, 13 . When comparing the expression of oncRNAs in these highly metastatic cells relative to their poorly metastatic parental lines, we noted one oncRNA with significantly increased levels in highly metastatic cells ( Fig. 2a ). This 45-nucleotide oncRNA mapped to the 3′ end of the TERC gene, which encodes the RNA component of telomerase ( Fig. 2b ). As such, we named this previously unknown smRNA T3p (for TERC 3′ RNA). Analysis of our previously published smRNA-seq dataset from the same poorly and highly metastatic pairs of cell lines 7 corroborated the higher expression of T3p in highly metastatic cells ( Fig. 2c ). We validated this upregulation of T3p expression in metastatic cells using quantitative real-time PCR (qPCR) ( Fig. 2c ). In our smRNA-seq dataset, we also observed T3p expression across our panel of breast cancer cell lines, but not in HMECs ( Supplementary Fig. 2a ).
We then investigated whether increased expression of T3p is associated with breast cancer pathogenesis. We first analyzed approximately 200 matched normal and breast cancer tumor tissue samples from TCGA-BRCA (The Cancer Genome Atlas for Breast Cancer) and noted that consistent with its classification as an oncRNA, the expression of T3p was highly cancer-specific ( Fig. 2d ). We then included the entire TCGA-BRCA dataset (around 1,000 tumor samples) in this analysis and observed that T3p, which was not detected in the majority of normal samples, was present at relatively high levels in tumor biopsies ( Fig. 2e and Supplementary Fig. 2b ). Notably, consistent with the higher expression of T3p in highly metastatic cells, we observed a significant association between patient survival and T3p expression, but not with TERC expression ( Fig. 2f and Supplementary Fig. 2c ). Higher expression of T3p in clinical breast cancer samples was also significantly correlated with advanced breast cancer ( Fig. 2g ). Stratification of these tumor samples by hormone receptor and HER2 status showed no strong association between T3p levels and expression of a specific receptor ( Supplementary Fig. 2d ). Finally, we also noted increased expression of T3p in PDX breast cancer models relative to normal epithelial tissue, as well as in highly metastatic PDX models relative to poorly metastatic PDX models ( Supplementary Fig. 2e these results establish the oncRNA T3p as a cancer-specific biomarker with robust prognostic value.
T3p acts as a broad regulator of gene expression in breast cancer cells.
The strong association between T3p expression and breast cancer progression from multiple independent datasets raised the possibility that T3p may play a direct and functional role in breast cancer progression. To elucidate its molecular function, we first investigated whether modulating T3p expression levels had any regulatory consequences. To answer this question, we silenced T3p by transfecting highly metastatic MDA-LM2 breast cancer cells with antisense locked nucleic acid oligonucleotides (LNAs) targeting T3p or with control LNAs. We then performed gene expression profiling to measure the genome-wide regulatory impact of silencing T3p. Notably, we observed a highly significant change in the gene expression landscape of the cells after T3p inhibition, affecting thousands of genes ( Fig. 3a ). This is on par with the impact of many well-established post-transcriptional regulators such as miRNAs 1, 14 .
However, the full-length TERC transcript remained a potential confounding factor, as the T3p-targeting LNA may also influence TERC function, which in turn could be responsible for the observed gene expression changes. To distinguish between these two possibilities, we used two independent approaches. First, in addition to using a nontargeting control LNA, we also used an LNA complementary to a sequence upstream of T3p, thus only targeting full-length TERC. Gene expression changes induced by the anti-T3p LNA were similar regardless of whether the scrambled control or anti-full-length TERC LNA was used as the reference ( Supplementary Fig. 3a ), indicating that LNA interaction with full-length TERC does not induce the same magnitude of gene expression changes generated by T3p inhibition. To further strengthen these findings, we performed a gain-of-function experiment by transfecting MDA-MB-231 breast cancer cells with either a synthetic T3p mimetic or a control scrambled oligonucleotide and then performed gene expression profiling. We again observed a significant change in the gene expression landscape in the mimetic compared to control transfected cells, similar to the change seen with LNA transfection. Notably, these mimeticinduced gene expression changes were generally anticorrelated with those observed in the loss-of-function LNA experiment (Fig. 3b,c) . This is consistent with our expectation that anti-T3p LNAs and T3p Mann-Whitney U-test was used to calculate the P value. Violin plots show the distribution along the minima and maxima for each cohort (median = 0 for normal and 0.34 for BRCA). f, Survival analysis in the TCGA-BRCA dataset for patients stratified into tertiles based on the expression of T3p in their tumors. All tertiles are shown. P value calculated from a two-sided log-rank test. The hazard ratio is equal to 0.5 for the low versus high tertiles. g, Expression of T3p across normal, stage I, and stage II and III samples in the TCGA-BRCA dataset shown as violin and box plots (quartiles). Normal, n = 104 (median = 0); stage I, n = 169 (median = 0.42); stage II-III, n = 799 (median = 0.46). The violin plots show the distribution along the minima and maxima. The box plots show the quartiles. The whiskers indicate quartile ± interquartile range. Outliers are also shown as points. P values were calculated using a two-way Mann-Whitney U-test.
mimetics should elicit opposite gene expression changes. Together, these observations establish T3p as a broad regulator of gene expression in breast cancer cells.
T3p promotes breast cancer metastasis. Given the broad regulatory effect of T3p on gene expression and its association with metastasis and with poor survival in breast cancer, we next investigated whether this oncRNA could affect metastasis in vivo. To test this, we transfected highly metastatic MDA-LM2 cells with anti-T3p LNAs and injected these cells into the venous circulation of immunocompromised mice and followed their metastatic colonization over time using in vivo imaging. We observed that cells transfected with anti-T3p LNAs had a significantly reduced capacity to colonize the lung (Fig. 3d ). Gross histology of lungs from each cohort also revealed a significantly lower number of visible metastatic nodules in the lungs of mice injected with T3p LNA-transfected cells ( Supplementary  Fig. 3b ). This observation indicates that even transient inhibition of T3p can lead to lower metastatic capacity. Given that T3p and TERC share a common sequence, RNA interference-mediated inhibition of T3p is not a suitable strategy for isolating its function. Therefore, to achieve stable and sustained inhibition of T3p, we took advantage of Tough Decoy (TuD) sponges-hairpin-shaped bulged RNAs that contain two recognition sites that bind and sequester the smRNA of interest 15 . We generated cells that stably expressed TuD RNAs targeting T3p and performed additional lung colonization assays. TuD-mediated inhibition of T3p resulted in a similarly substantial reduction in the metastatic capacity of MDA-LM2 cells ( Fig. 3e and Supplementary Fig. 3c ). Notably, T3p inhibition did not significantly affect in vitro proliferation rates, cell cycle length or in vivo tumor growth rates of MDA-LM2 cells ( Supplementary Fig. 3d -f). To ensure these observations were not limited to the MDA-LM2 background, we also performed in vivo lung colonization assays with an independent breast cancer cell line, HCC1395. Consistent with our previous results, T3p inhibition in HCC1395 cells also resulted in decreased metastatic capacity and also did not affect in vitro proliferation rates ( Supplementary Fig. 3g ,h). Together, these observations strongly support a functional role for T3p in driving breast cancer metastasis.
Biogenesis of T3p in breast cancer cells.
We next sought to identify the T3p biogenesis pathway to explain its cancer-specific expression. We considered two possibilities for the biogenesis of T3p: (i) transcription from a cryptic promoter, and (ii) nucleolytic digestion of the TERC RNA. Ectopic transcription has been implicated in a variety of diseases 16 ; to assess this possibility, we examined RNA-sequencing and global run-on sequencing datasets from MDA-MB-231 cells and did not find any evidence for increased active transcription at the T3p locus. Consistent with this, RNA PolII chromatin immunoprecipitation followed by sequencing datasets also show no increased RNA PolII binding at the 5′ end of T3p, suggesting that T3p is not a product of ectopic transcription ( Supplementary Fig. 4a ). These findings suggested that T3p may be a byproduct of TERC RNA digestion or cleavage. Supporting this, we noted a significant positive correlation between TERC and T3p expression across the TCGA-BRCA dataset ( Supplementary Fig. 4b ).
To identify RBPs and nucleases that may be involved in the biogenesis of T3p, we first performed a co-expression network analysis 17 centered on T3p expression by analyzing the TCGA-BRCA dataset to identify those genes whose expression was significantly correlated with the expression of T3p. We then further limited our candidates to RBPs and nucleases to focus on factors that could have a direct effect on T3p biogenesis. We also required candidates to be (i) overexpressed in breast tumors relative to normal tissue, and (ii) upregulated in highly metastatic MDA-LM2 cells compared to poorly metastatic MDA-MB-231 cells. This analysis yielded two candidates: the double-stranded RBP TARBP2 and the doublestranded RNA-specific endoribonuclease DROSHA (Fig. 4a ). 
Fig. 3 | t3p regulates gene expression and drives metastatic progression. a, A volcano plot of gene expression changes following transfection of anti-
T3p LNA relative to scrambled LNA in highly metastatic MDA-LM2 cells. n = 2 biologically independent experiments. P and log fold change values were calculated using the Lumi package (significance threshold was set at two-tailed adjusted P = 0.01). b, Scatter plot comparing gene expression changes induced by anti-T3p LNA in MDA-LM2 cells versus T3p mimetic in MDA-MB-231 parental cells. Reported is the associated Pearson correlation (R = − 0.234, P ≈ 0). c, Venn diagrams showing the overlap of genes upregulated in LNAtransfected MDA-LM2 cells and downregulated in T3p mimetic-transfected MDA-MB-231 cells, as well as overlap of genes downregulated in LNAtransfected MDA-LM2 cells and upregulated in T3p mimetic-transfected MDA-MB-231 cells. P values were obtained from a hypergeometric distribution. d, Bioluminescence imaging plot of lung colonization by MDA-LM2 cells transfected with anti-T3p LNA (LNA-T3p) or scrambled LNA (LNA-Scr); n = 4 (LNA-Scr) or n = 5 (LNA-T3p) biologically independent animals per cohort; mean ± s.e.m. are reported for each day; two-way ANOVA. Area under the curve is presented as mean ± s.d.; P was calculated using a one-tailed Mann-Whitney U-test. AU, arbitrary units. e, Bioluminescence imaging plot of lung colonization by MDA-LM2 cells stably expressing T3p-TuD or a control hairpin; n = 5 biologically independent animals per cohort; mean ± s.e.m. are reported for each day; two-way ANOVA. Area under the curve is presented as mean ± s.d.; P was calculated using a one-tailed Mann-Whitney U-test.
The expression of each of these genes is also correlated with T3p expression ( Supplementary Fig. 4c ). Notably, our published TARBP2 HITS-CLIP (high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation) data 18 showed a direct interaction between TARBP2 and the 3′ end of TERC (Fig. 4b ).
We also analyzed recently published data from DROSHA formaldehyde CLIP-seq 19 , and observed evidence of DROSHA binding to the 3′ end of TERC (Fig. 4c ). Together, these analyses suggest that TARBP2 and DROSHA are candidates that are directly involved in the nucleolytic biogenesis of T3p from TERC.
To directly test the effect of TARBP2 and DROSHA on T3p levels in MDA-MB-231 cells, we used siRNAs to knock down each factor, as well as DGCR8 and DICER1 as controls. We then performed smRNA-seq to measure changes in T3p levels. RNA interferencemediated knockdown of either TARBP2 or DROSHA resulted in a substantial reduction in T3p levels, whereas silencing DICER or DGCR8 did not affect T3p levels (Fig. 4d ). We confirmed this observation using qPCR ( Supplementary Fig. 4d ). Consistently, in TCGA-BRCA, T3p levels are higher in samples that have higher expression of both DROSHA and TARBP2 ( Supplementary Fig. 4e ). Together, these results implicate TARBP2 and DROSHA in the biogenesis of T3p from TERC, and also provide an explanation for the presence of T3p in cancer cells and its absence in normal cells. Increased TERC expression and telomerase activity are hallmarks of tumorigenesis. This increase in TERC, combined with higher expression of TARBP2 and DROSHA in cancer cells, provides an explanation for the cancer-specific generation of T3p. As we will demonstrate below, the production of T3p as an oncRNA provides an opportunity for cancer cells to modulate the expression of key promoters of metastatic progression.
T3p exerts its regulatory effects through interaction with the RISC complex. After assessing the regulatory and phenotypic consequences of T3p expression in breast cancer cells, we determined the regulatory mechanism(s) through which T3p drives deregulated and pathologic gene expression. To address this, we searched a large dataset of binding preferences for RBPs 20 to find potential T3p-binding proteins, and we similarly searched a curated database of CLIP experiments that provides in vivo binding sites for roughly 100 RBPs 2,7,21-24 . The most robust of these observed and inferred interactions was a highly significant and precise interaction between T3p and Argonaute 2 (AGO2) in a previously published CLIP-seq 18, 19 . d, Normalized T3p levels in smRNA-seq data from MDA-LM2 cells transfected with each of the indicated siRNAs. n = 2 biologically independent samples. Normalized expression was calculated using the DESeq2 package (center = mean). e, Genome browser view of AGO2 CLIP 24 read density at the T3p locus. f, A heat map depicting the activity of miRNAs predicted to be targeted by T3p in vivo. The miRNA seed sequences were used to evaluate gene expression changes in their targets induced by an anti-T3p LNA. For each listed miRNA, we observed a significant enrichment of the miRNA target genes among those downregulated in T3p-silenced cells. Also shown are the mutual information (MI) values (measured in bits) and the associated z score for each association 26 . Yellow boxes with red borders indicate significant enrichment and blue boxes with dark-blue borders indicate significant depletion. n = 2 biologically independent experimental comparisons. g, AGO2-CLASH qPCR was performed on candidate and control miRNAs (mir-940 and mir-107) to test for in vivo interactions with T3p. Assays performed in biological duplicate (indicated by the symbols).
dataset 24 . Unlike TARBP2 and DROSHA, which show binding to regions of TERC outside of T3p, the AGO2 binding signal is confined to the T3p boundaries ( Fig. 4e ). This clear demarcation suggests that AGO2 binds T3p but not TERC. We confirmed the interaction between T3p and AGO2 using ultraviolet-light crosslinking and AGO2 immunoprecipitation followed by qPCR in MDA-MB-231 cells ( Supplementary Fig. 4f ). The interaction between T3p and AGO2 raised the possibility that the broad regulatory effects of T3p could be carried out either by T3p acting as a miRNA, leading to targeted silencing of downstream transcripts, or as inhibitor of AGO2-miRNA complex activity. To test the first possibility, we performed an unbiased search for all 7-mers across T3p that could act as seed sequences. For each 7-mer, we investigated whether the levels of the mRNAs that contained its complementary sequence changed when T3p levels were modulated using transfected LNAs or exogenous mimetics. The absence of a seed sequence that meets this criterion and the fact that T3p is longer than conventional miRNAs, mostly rules out the former model. We next hypothesized that T3p may interfere with the activity of the RISC complex by competing with endogenous miRNA targets for binding. To assess this possibility, we used three criteria to identify candidate miRNAs that may be targeted by T3p: (i) the ability of the miRNA to form a stable duplex with T3p ( Supplementary Fig. 4g ), (ii) downregulation of predicted mRNA targets of the miRNA when T3p is silenced, and (iii) the miRNA is expressed at a level similar to or lower than the expression of T3p (that is, favorable stoichiometry). We reasoned that decreased T3p expression should result in increased miRNA activity, which in turn would decrease levels of the mRNA targets of the miRNA. We identified a set of five miRNAs that satisfied these criteria ( Fig. 4f and Supplementary Fig. 4h ,i). To test whether any of these miRNAs directly interact with T3p in the RISC complex, we used a qPCR derivative of the CLASH method 25 (see Methods for details). As shown in Fig. 4g , this assay provided evidence that RISC-associated miR-10b-5p (miR-10b) and miR-378c-5p (miR-378c) directly interact with T3p.
As a consequence of this T3p-mediated interaction, the targets of these miRNAs also responded to LNA-mediated inhibition of T3p activity. Consistent with this observation, the miR-10b and miR-378c regulons were upregulated in the presence of T3p mimetic oligonucleotides as well as in MDA-LM2 cells, in which the endogenous T3p levels are higher than the levels in MDA-MB-231 cells (Fig. 5a ). Together, these results provide further evidence that T3p is a modulator of miRNA activity in breast cancer cells.
To identify the downstream genes that drive the phenotypic consequences of T3p expression, we performed a search for the most robust targets of this pathway. To do this, we first identified genes predicted to be targeted by miR-10b or miR-378c 26 , and then searched for those also (i) upregulated in large breast cancer datasets (TCGA-BRCA), (ii) downregulated after LNA-mediated inhibition of T3p, and (iii) upregulated in MDA-LM2 compared to MDA-MB-231 cells. We calculated the sum of all ranks across these datasets, and identified NUPR1 and PANX2 as the two top candidate genes. These genes, which are predicted targets of miR-10b and miR-378c, have increased levels in highly metastatic MDA-LM2 cells, in which T3p expression is also elevated ( Fig. 5b and Supplementary Fig. 5a ). We also observed that T3p, NUPR1 and PANX2 expression is upregulated in bone, but not brain metastatic cells lines derived from the MDA-MB-231 cell line 13, 27 ( Supplementary Fig. 5b ). Moreover, NUPR1 and PANX2 expression was positively correlated with T3p expression and negatively correlated with miR-10b and miR-378c expression across a set of ten breast cancer PDX models as well as a panel of nine breast cancer cell lines ( Supplementary Fig. 5c ). Furthermore, expression levels of NUPR1 and PANX2 were reduced after transfection with the anti-T3p LNA in both MDA-LM2 and HCC38 cells ( Supplementary  Fig. 5d,e ). We observed that inhibition of miR-10b and miR-378c using antisense inhibitors targeting these miRNAs resulted in an increase in the expression of NUPR1 and PANX2 mRNA (Fig. 5c ). We also observed a decrease in the expression of NUPR1 and PANX2 in the presence of T3p-TuD (Fig. 5d ). To assess whether these observed changes in expression were because of post-transcriptional changes in RNA stability rather than transcriptional modulation, we also measured NUPR1 and PANX2 pre-mRNA levels after T3p, miR-10b and miR-378c inhibition and noted little change in the pre-mRNA levels of these genes, further implicating RNA stability as the underlying cause of the observed gene expression changes ( Supplementary Fig. 5f,g) . In support of these findings, we observed that NUPR1 and PANX2 mRNA coimmunoprecipitated with AGO2 and that inhibition of miR-10b and miR378c resulted in the loss of this association ( Supplementary Fig. 5h ). To test whether NUPR1 and PANX2 are downstream of T3p as well as miR-10b and miR-378c, we used qPCR to measure NUPR1 and PANX2 levels in cells transfected with inhibitors of T3p and the miR-10b and miR378c miRNAs. This showed that PANX2 and NUPR1 expression decreases after T3p downregulation only when the miRNA levels are not perturbed ( Supplementary Fig. 5i ). Taken together, these observations establish NUPR1 and PANX2 as downstream targets of this T3p-mediated regulatory pathway.
Consistent with increased expression of these genes in highly metastatic cells, analysis of multiple breast cancer gene expression datasets showed a negative association between the expression of these genes in breast tumors and patient survival, as well as increased expression of these genes in advanced breast cancers ( Fig. 5f and Supplementary Fig. 5j,k) . We did not observe any significant association between NUPR1 or PANX2 expression and breast cancer subtype ( Supplementary Fig. 5l ). Together, these clinical associations support a role for NUPR1 and PANX2 in breast cancer progression. To experimentally test this possibility, we used CRISPR interference (CRISPRi) to knock down these genes in the highly metastatic MDA-LM2 cells. As shown in Fig. 5e , decreased expression of these genes significantly reduced metastatic colonization of the lungs in xenografted mice. Additionally, we stably expressed T3p-TuD or the control decoy in these NUPR1 and PANX2 knockdown cells. We then performed in vivo metastatic lung colonization assays with these lines and, consistent with the idea that T3p influences metastasis through these genes, we observed no further reduction in metastatic lung colonization when T3p was inhibited ( Supplementary Fig. 5m ). In vitro assays showed little change in the proliferation rates of these NUPR1 and PANX2 knockdown cells (data not shown), indicating that the observed effect on metastasis is not due to a general reduction in cell proliferation. These results establish T3p as a promoter of breast cancer progression (Fig. 5g ).
Specific oncRNAs are present in the extracellular compartment. We next investigated whether oncRNAs could be detected in the extracellular space, a beneficial characteristic for clinical markers. To explore this possibility, we isolated RNA from conditioned medium obtained from eight breast cancer cell lines as well as HMECs. smRNA-seq of this material revealed that of our 201 annotated oncRNAs, close to half were detected in the conditioned medium from one or more of these breast cancer lines but not in HMECs (Fig. 6a) , demonstrating that oncRNAs are present in the extracellular space. Given that extracellular vesicles have previously been reported as a biologically functional destination for smRNAs 28 , we investigated whether oncRNAs were present in extracellular vesicles. To do this, we sequenced RNA purified from extracellular vesicles isolated from the same conditioned medium that we used for smRNA-seq in Fig. 6a (Supplementary Fig. 6a ), and found that of the 201 annotated oncRNAs, a third were observed in the extracellular vesicles from one or more of these breast cancer lines but not in HMECs. There is a small positive correlation between oncRNA levels in cells and conditioned medium, as well as oncRNA levels in cells and extracellular vesicles, suggesting that there are elements of both passive and active secretion of oncRNAs into the extracellular space ( Supplementary Fig. 6b ). Additionally, analysis of publicly available exosomal smRNA-seq data from MDA-MB-231 cells 29 showed that 20% of oncRNAs, including T3p, were present in this independent dataset ( Supplementary Fig. 6c ). Given that extracellular oncRNAs are specifically generated and secreted by cancer cells, they may potentially serve as a fingerprint for the underlying tumor and would be accessible through liquid biopsies. To assess this possibility, we used a machine-learning approach by training a gradientboosted classifier (GBC) on the TCGA-BRCA dataset to distinguish normal tissue from breast cancer biopsies using oncRNAs as 
Fig. 5 | t3p-mediated inhibition of miR-10b and miR-378c results in overexpression of metastasis promoters NuPR1 and PANX2
. a, Heat maps showing significant upregulation of miR-10b and miR-378c targets after transfection of MDA-MB-231 cells with T3p mimetic. Significant upregulation of these targets was also observed in highly metastatic MDA-LM2 cells compared to poorly metastatic MDA-MB-231 cells. Mutual information values (measured in bits) and the associated z scores are also shown. n = 2 biologically independent experimental comparisons. b, qPCR for NUPR1 and PANX2 in MDA-LM2 and the parental MDA-MB-231 cell lines; n = 3 biologically independent experiments. c, qPCR for NUPR1 and PANX2 in control, miR-378c-and miR-10b-knockdown (KD) cells; n = 3 biologically independent experiments. d, NUPR1 and PANX2 expression levels in cells expressing T3p-TuD relative to control cells; n = 3 biologically independent experiments. A one-tailed Mann-Whitney U-test was used to calculate P values in b-d. e, Bioluminescence imaging plot of lung colonization by MDA-LM2 cells stably expressing CRISPRi guide RNAs against NUPR1 or PANX2, or a control guide; n = 4 biologically independent animals per cohort. Statistical significance of knockdown versus control cohorts was measured using two-way ANOVA. The area under the curve was also calculated for each mouse; mean ± s.d. are shown (change in normalized lung photon flux times days elapsed); P values were calculated using a one-tailed Mann-Whitney U-test. f, NUPR1 and PANX2 expression levels were measured using qPCR across 96 clinical samples composed of normal tissue and tissue from the indicated breast cancer stages. P values were calculated using a one-tailed Mann-Whitney U-test (without adjustment). g, A schematic of model for T3p-mediated control of target genes in highly metastatic cells.
features. We first investigated whether this classifier could correctly identify serum samples collected from healthy individuals as 'normal. ' To do this, we processed raw smRNA-seq data from 35 healthy volunteers (11 samples from the exRNA atlas 30 and 24 samples from a previous study 31 ) to measure circulating oncRNAs and used our previously trained GBC to classify this data. We found that our GBC successfully labeled 34 out of 35 samples as normal. We then tested the same classifier on a dataset of circulating smRNAs from 40 patients with breast cancer 32 and successfully classified 37 out of 40 as breast cancer patient samples. The strong overall performance of our classifier in distinguishing sera collected from healthy individuals and patients with breast cancer (area under the receiver operating characteristic curve (AUROC) = 0.97; Supplementary Fig. 6d ) further highlights the cancer-specificity and possible clinical utility of oncRNAs. For example, T3p alone showed markedly different expression levels in the serum of 40 patients with breast cancer and healthy volunteers ( Fig. 6b and Supplementary Fig. 6e ). We also used qPCR to measure T3p levels in RNA from extracellular vesicles from an independent set of serum samples from patients with breast cancer and healthy volunteers. We observed significantly increased T3p levels in extracellular vesicles isolated from serum from stage I and II patients compared to the unaffected controls ( Supplementary  Fig. 6f ). These data demonstrate that T3p is present in circulating extracellular vesicles in human patients with cancer, and may be useful in detecting stage I breast cancers and well as more advanced cancer stages. It important to note that although this classifier is trained on oncRNA levels in tumor biopsies, it can correctly classify serum samples, highlighting the fact that circulating oncRNAs can directly reflect the predictive oncRNA content of the underlying tumor. To test the possibility that any random classifier can perform similarly well, we also trained a GBC on features (that is, smRNAs) and labels (that is, normal versus tumor) randomly selected from the TCGA dataset. As expected, this random classifier performed poorly on the 35 healthy and 40 cancer samples (AUROC = 0.422).
We then compared the performance of circulating oncRNAs to that of previously reported breast cancer serum miRNA signatures in classifying these clinical samples. To do so, we compiled a set of 36 miRNA signatures associated with breast cancer tumorigenesis and progression from four independent studies [33] [34] [35] [36] . These independent studies did not identify any overlapping miRNAs, highlighting the high degree of variation involved in circulating miRNA quantification. Taking the same approach, we used these previously published miRNAs to train a GBC on the TCGA-BRCA dataset. Testing this miRNA-based classifier on the serum smRNA dataset showed a relatively poor performance (AUROC = 0.69; Supplementary  Fig. 6g ). These results indicate that serum miRNA signatures do not reflect changes in miRNA expression levels of the underlying tumor and, unlike oncRNAs, may not directly originate from cancer cells. Consistent with this notion, a fivefold cross-validation of a miRNA-based classifier on the serum smRNA dataset showed 89% (± 11%) accuracy, which is substantially superior to its performance when trained on the TCGA-BRCA dataset. However, oncRNAs performed better in this sample type as well: a fivefold cross-validation of an oncRNA-based classifier achieved 98% (± 8%) accuracy in serum smRNA data. On the basis of these results, we surmise that detection of circulating oncRNAs may potentially act as a more reliable readout of the underlying cancer.
discussion
Through the application of a systematic and unbiased discovery platform that includes breast cancer cell lines, PDX models and clinical breast cancer data, we have identified a set of 201 RNA species that are specifically expressed in breast cancer cells and are largely undetected in normal cells and tissues. These RNA molecules, which we have collectively named oncRNAs, provide a pool of novel potential regulators that breast cancer cells may use to engineer new regulatory circuits. We compared poorly and highly metastatic cells to investigate whether any of these oncRNAs are used by cancer cells to promote disease progression. We discovered that T3p, an oncRNA generated from TERC RNA, is strongly associated with breast cancer progression both in cell line models and in clinical datasets. We then used computational and experimental methodologies to (i) establish its role as a regulator of gene expression and a promoter of breast cancer metastasis, (ii) characterize its regulatory function, and (iii) uncover its biogenesis pathway. Finally, we discovered that oncRNAs can be detected in circulating and extracellular vesicle compartments originating from cancer cells, and therefore have the potential to play functional parts in non-cell autonomous pathways.
Our findings introduce a new paradigm of cancer progression in which tumors evolve new regulatory pathways en route to metastatic spread. Furthermore, these cancer-specific post-transcriptional regulatory pathways comprise a set of potential novel therapeutic targets that are exclusive to cancer cells. Moreover, as circulating oncRNAs provide a snapshot of the regulatory state of the cancer cells, oncRNA profiling presents an opportunity to obtain highly tumor-specific data from liquid biopsies, and may complement current diagnostic methods. Therefore, oncRNA profiling in serum samples could act as an informative digital fingerprint-that is, a profile of the presence or absence of each of the oncRNAs-of the underlying tumor. Although our study focused on the role of T3p in breast cancer metastasis, the approaches and concepts presented here are generalizable and can be applied to other cancer types. Taken together, our findings raise the possibility that further examination of the cancerspecific RNA landscape may yield novel strategies in developing diagnostic and therapeutic methods in breast cancer.
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Methods
Tissue culture. All cells were cultured in a 37 °C, 5% CO 2 humidified incubator. The cell lines MDA-MB-231, MDA-LM2, CN34-par, CN34-Lm1a, MCF7 and MDA-MB-453 were propagated in DMEM base medium supplemented with 4.5 g l −1 glucose, 10% FBS, 4 mM l-glutamine, 1 mM sodium pyruvate, penicillin (100 U ml −1 ), streptomycin (100 μ g ml −1 ) and amphotericin B (1 μ g ml −1 ). The cell lines HCC1395, ZR-75-1 and HCC38 were propagated in RPMI 1640 base medium supplemented with 10% FBS, 2 mM l-glutamine, penicillin (100 U ml −1 ), streptomycin (100 μ g ml −1 ) and amphotericin B (1 μ g ml −1 ). The SK-BR-3 cell line was propagated in McCoy's 5a modified medium supplemented with 10% FBS, penicillin (100 U ml −1 ), streptomycin (100 μ g ml −1 ) and amphotericin B (1 μ g ml −1 ). HMECs were obtained from Thermo Fisher Scientific and propagated in HuMEC ready medium (Thermo Fisher Scientific).
Extraction and sequencing of small and extracellular-vesicle RNAs. Preparation of conditioned medium for isolation of RNA from extracellular vesicles and total conditioned medium was carried out by seeding cells at a density of 7 × 10 5 . After 24 h, cells were washed twice with PBS and 10 ml exosome-depleted medium was added. Then, 48 h later, medium was collected by spinning at 200g for 15 min and taking the supernatant. Exosome-depleted medium was prepared by using exosome-depleted FBS (Thermo Fisher Scientific) instead of FBS. Exosomedepleted HMEC medium was prepared by centrifuging the bovine pituitary extract medium component at 100,000g at 4 °C for 16 h and adding the supernatant to the complete medium.
Extracellular-vesicle RNA was isolated from 5 ml conditioned medium, prepared as outlined above, using the Cell Culture Media Exosome Purification and RNA Isolation kit (Norgen Biotek). RNA from conditioned medium was isolated from 400 μ l total conditioned medium using the miRNeasy Serum/Plasma kit (Qiagen). Total cellular smRNA samples were extracted using the Norgen Biotek Small RNA Purification kit according to the manufacturer's protocol. RNA samples were subsequently prepared for high-throughput sequencing with the NEXTflex Small RNA Sequencing Kit v3 using the manufacturer's protocol (Bioo Scientific). The resulting libraries were then sequenced and processed as recommended by the manufacturer. In brief, cutadapt (v1.4; https://github. com/marcelm/cutadapt) was used to remove the adapter sequences and trim the degenerate sequences at the beginning and end of each read. We then used Bowtie2 37 (v2.3.3) to align the resulting sequences to the human genome (build hg38). The resulting BAM files were then sorted and converted to BED for further analysis.
Extracellular-vesicle RNA was isolated from serum samples using the Plasma/ Serum Exosome Purification and RNA isolation kit (Norgen Biotek) according to the manufacturer's instructions.
TCGA-BRCA smRNA-seq data and identification of oncRNAs. Reads from the TCGA-BRCA project were downloaded from the Genomic Data Commons (GDC) in BAM format (hg38) and the samples were annotated using the GDC API. After conversion to the BED format, the Piranha package 7 was used to identify the expressed smRNA loci. The resulting loci were merged across all samples using mergeBed 38 to create a comprehensive list of smRNA loci expressed in breast tissue and breast cancer.
By enumerating the smRNA sequences obtained from breast cancer cell lines and HMECs, we generated a count table for each smRNA locus. We then normalized the resulting table by library size and retained only those loci with no observed reads across the three HMEC replicates. We used two independent statistical tests to compare either all cancer cell lines or each subtype individually (triple-negative breast cancer, HER2 + and luminal breast cancer): first, we used the DESeq2 39 package in R to calculate an adjusted P value. Second, we used a Fisher's exact test to compare the presence and absence of each smRNA. We selected those loci with either an adjusted P < 0.05 in the former or P < 0.1 in the latter test across all comparisons. There were 437 loci that satisfied these criteria (shown in Fig. 1a ). For visualization, we max-normalized each row and performed a k-means clustering (k = 3).
For the TCGA-BRCA database, we generated a similar count table across all subtype-annotated samples (based on PAM50 classification) and all smRNA loci and normalized the resulting table to generate a counts-per-million reads (c.p.m.) table. In order to identify 'orphan' smRNAs, that is, those smRNAs that were mostly absent from normal cells, we retained only the loci with their 90th percentile expression in normal samples below 0.5 c.p.m. Of the 437 loci above, 268 passed this step. We then performed Fisher's exact tests to compare the presence of all smRNAs across the tumor samples and normal biopsies. We performed similar comparisons between normal samples and each of the breast cancer subtypes. We then retained those loci that were significant in at least one of these tests with an adjusted P value of P < 0.05. In total, 201 of the smRNAs satisfied this final step and were thus classified as oncRNAs. We confirmed that none of these smRNAs were previously annotated as miRNAs, small nucleolar RNAs, or tRNAs.
smRNA-seq of PDX models and normal epithelial samples. All human samples used to generate PDX tumors, as well as the human nontumor samples, were previously described 40 . smRNA profiling and data preprocessing was carried out by Q 2 Solutions. The abundance of oncRNAs in these samples was determined as described above.
Comparing oncRNA expression between poorly and highly metastatic cells.
We used the R package DESeq2 to compare expression of oncRNAs between parental cell lines in Fig. 1 (MDA231 and CN34) and their highly metastatic in vivoselected derivatives to identify those oncRNAs that were significantly upregulated in highly metastatic cells. We identified T3p in this analysis, which we also confirmed in a smRNA dataset that we had previously generated for these lines 7 .
In addition, we also performed qPCR assays. For this, we extracted smRNAs from MDA-MB-231 parental cells and their highly metastatic MDA-LM2 derivative cell line (microRNA Purification Kit, Norgen) and performed stem-loop qPCR. T3p primers: 5′ -CCAGTGCAGGGTCCGAGGTA-3′ and 5′ -CCCAGGACTCGGCTCACAC-3′ . 18S (endogenous control) primers: 5′ -GTAACCCGTTGAACCCCATT-3′ and 5′ -CCATCCAATCGGTAGTAGCG-3′ .
T3p expression and clinical association in the TCGA-BRCA dataset. We used the metadata that was included in the TCGA-BRCA dataset to perform survival analysis based on T3p expression in tumor samples. We stratified the patients based on T3p levels and generated Kaplan-Meier curves using all tertiles and performed log-rank (Mantel-Cox) tests to calculate the associated P value. We similarly used the clinical data to compare T3p expression across early-and latestage tumors (one-tailed Mann-Whitney U-test).
T3p modulation and gene expression profiling. We used miRCURY LNA inhibitors (Exiqon) against the following sequences: T3p: 5′ -CAGGAC TCGGCTCACACATGC-3′ ; TERC: 5′ -TTGTCTAACCCTAACTGAGAAGG-3′ ; scrambled: 5′ -AGACGACAGCTGGATCACACG-3′ . Similarly, we used T3p mimetics (IDT): 5′ -rU*rCrCrCrUrGrArGrCrUrGrUrGrGrGrArCrGrUrGrCrArC rCrCrArGrGrArCrUrCrGrGrCrUrCrArCrArCrArUrG*rC-3′ (T3p mimetic) and 5′ -rA*rGrArCrGrArCrArGrCrUrGrGrArUrCrArCrArC*rG-3′ (control). We then transfected the LNAs in the highly metastatic MDA-LM2 cells and the mimetics in the parental MDA-MB-231 cells and performed gene expression profiling and differential gene expression analysis as previously described 7 .
Tough Decoys and in vivo lung colonization and tumor growth assays. MDA-LM2 cells were transfected with anti-T3p or scrambled LNA (same as above) and after 48 h, cells were injected through the tail vein into the venous circulation of female immunocompromised NOD/SCID/gamma (NSG) mice (2.5 × 10 4 per mouse; n = 5 per cohort). In vivo imaging and comparison of curves was performed as previously described 18 . Lungs from at least three mice per cohort (middle signal) were then extracted, fixed, sectioned and stained with H&E, and tumor nodules were quantified as previously described 18 .
To generate stable inhibition of T3p, we designed TuDs against this smRNA in a lentiviral backbone under a RNA PolIII promoter (pLKO.1). We then stably transduced MDA-LM2 cells and performed lung colonization assays, injecting 5 × 10 4 cells via tail vein per NSG mouse. HCC1395 cells were similarly transduced and injected at 2 × 10 5 cells per NSG mouse.
Orthotopic tumor growth assays were performed by injecting 2.5 × 10 5 cells resuspended in 50 μ l PBS mixed with 50 μ l Matrigel into the mammary glands of age-matched 6-8-week-old female NSG mice using a 28-gauge needle. Tumor volume was determined using calipers to measure the tumor length (L) and width (W) every 2 d and calculated using the formula π LW2/6. The experimental end point was reached once tumors reached a volume of 800 mm 3 .
Cell proliferation. In vitro cancer cell proliferation assays were performed by seeding 5 × 10 4 cells at day 0 and then counting them in triplicate on day 3 and day 5. The slope of the best fitted line between the log of cell counts and days is the reported proliferation rate (logN t = logN 0 + rt where t is the time in days and r the proliferation rate per day).
For cell cycle analysis, cells were grown to 80% confluency in 6-cm plates, collected and fixed in 70% ethanol. Cells were then pelleted and resuspended in 50 μ g ml −1 propidium iodide (Thermo Fisher Scientific) and 1 mg ml −1 RNase A (Thermo Fisher Scientific) and allowed to incubate for 1 h at 37 °C. A BD Aria2 flow cytometer was then used for FACS analysis; post-FACS analysis and cell cycle quantification was performed using the python package 'fcsparser' (https://github. com/eyurtsev/fcsparser/tree/master/fcsparser).
Coexpression analysis for finding T3p biogenesis factors.
To identify the regulators of T3p biogenesis, we listed the genes with known nuclease activity (Gene Ontology identifiers (GO) 0004540 and 0004525) and further added RBPs that are known to interact with these nucleases 41 . We then performed co-expression analysis between T3p levels and those of the genes on this list across the TCGA-BRCA dataset. We overlapped the genes with strong associations with those that are upregulated in highly metastatic MDA-LM2 cells and are also higher in breast cancer samples relative to normal biopsies in the TCGA-BRCA dataset. On the basis of these criteria, we identified seven candidates, two of which had known double-stranded RNA binding activity. Since the CR7 domain of TERC is structured (that is, forms double-stranded regions), we reasoned that these proteins, namely DROSHA and TARBP2, were the best candidates for followup. We used siRNAs (IDT) to knockdown DROSHA and TARBP2, as well as DGCR8 and DICER1, which are known to interact with DROSHA and TARBP2, respectively. We used the following target sequences: TARBP2, 5′ -ACCTGGG ATTCTCTACGAAATTCAGT-3′ ; DROSHA, 5′ -CCTTGATTGAGGTATAGTT CTTGTCT-3′ ; DICER1, 5′ -TGGTGCTTAGTAAACTCTTGGTTCCA-3′ ; and DGCR8, 5′ -CTGCAGGAGTAAGGACAGGAAGGTGC-3′ . After siRNA transfection and knockdown verification, we performed smRNA-seq as described above.
Identifying and validating miRNA targets of T3p. For each miRNA, we investigated whether their target regulon, predicted based on matches to their seed sequences, was significantly downregulated when T3p was silenced. For this, we used the motif discovery platform FIRE 26 to analyze the T3p LNA differential gene expression data against the list of miRNA seed sequences. For those miRNAs that passed this initial test, we used RNAHybrid 42 to further select those miRNAs that can form duplexes with T3p (with a maximum minimum free energy of − 14.0). We also required that these miRNAs were expressed at a similar or lower level than T3p in our smRNA profiling dataset. Finally, we performed AGO2-CLASH qPCR assays, based on the AGO2-CLASH method, to confirm direct interactions in vivo between candidate miRNAs and T3p.We used an AGO2 antibody (Proteintech 10686-1-AP) and used a preparation method similar to AGO2 HITS-CLIP 43 . In brief, samples were CIP-and PNK-treated on-bead after immunoprecipitation, and then T4 RNA ligase 1 (in the absence of the 3′ linker commonly used in CLIP experiments) was used to achieve proximity ligation. Samples were then treated with Proteinase K and the RNA was extracted and cleaned up (Zymogen RNA Clean & Concentrator kit). The T3p matching primer 5′ -TGTGAGCCGAGTCCTGGGTG-3′ , along with primers based on each of the candidate miRNAs, were used to perform qPCR (SYBR Green). Among the tested candidates, miR-10b and miR-378c showed strong evidence of physical interaction with T3p in vivo. We obtained predicted targets of these two miRNAs (StarBase) and confirmed their upregulation in the presence of T3p based on our gene expression profiles. AGO2 CLIP-qPCR was performed using the AGO2 HITS-CLIP immunoprecipitation method, without any nuclease digestion or other enzymatic treatment of the crosslinked RNA. Protein-RNA complexes were immunoprecipitated using an antibody to AGO2 (Proteintech 10686-1-AP) or rabbit IgG. After washing, RNA was isolated by treating beads with Proteinase K followed by phenol chloroform extraction. The relative abundance of NUPR1 and PANX2 in the resulting RNA was assessed by qPCR. To assess T3p and miR-378c copy numbers, we used synthetic RNA versions of these molecules (IDT) to create a standard curve with known concentrations of synthetic T3p and miR-378c. We then used qPCR to measure the concentration of T3p and miR-378c in smRNA extracted from 8 × 10 5 MDA-MB-231 cells by comparing the expression levels to the standard curve.
T3p downstream target selection and functional validation.
To identify downstream targets that are mediated by T3p expression in breast cancer cells, we used the following criteria: (i) targets of miR-10b and miR-378c (StarBase), (ii) upregulated in breast tumors (TCGA-BRCA dataset), (iii) upregulated in highly metastatic MDA-LM2 cells in which T3p is highly expressed, and (iv) downregulated when T3p inhibited. On the basis of these criteria, we identified NUPR1 and PANX2 as targets of T3p. We used qPCR to verify changes in the levels of these genes in response to modulations in components of this pathway. We used miRNA inhibitors (IDT) and Tough Decoys for this assay. Primer pairs used for qPCR measurement were: 5′ -AAGCAGAGACAGACAAAGCG-3′ and 5′ -TG GGCATAGGCATGATGAGA-3′ for NUPR1 mRNA; 5′ -AACCCAGATCT CTGTCCCTTT-3′ and 5′ -CCGCAGTCCCGTCTCTATT-3′ for NUPR1 pre-mRNA. Similarly, 5′ -CCAAGAACTTCGCAGAGGAAC-3′ and 5′ -GGGC AGGAACTTGTGCTCA-3′ were used for for PANX2 mRNA, and 5′ -AGCC CGTGTCTCCTCTT-3′ and 5′ -AGCTCCGTCCAGCAGTA-3′ for PANX2 pre-mRNA. We used HPRT1 as the endogenous control in these experiments: 5′ -GA CCAGTCAACAGGGGACAT-3′ and 5′ -CCTGACCAAGGAAAGCAAAG-3′ .
To examine the association between NUPR1 and PANX2 expression with breast cancer progression, we acquired 96 cDNA samples from breast cancer clinical specimens including 5 normal epithelial cell samples and 23 stage I, 30 stage II, 29 stage III and 9 stage IV metastatic biopsies (Origene). We then used SYBR Green qPCR to measure NUPR1 and PANX2 expression levels, using ACTB as the endogenous control.
We used CRISPRi guides to generate NUPR1 and PANX2 knockdown cells in the highly metastatic MDA-LM2 cells. The choice of CRISPRi was based on its minimal off-target effects. We achieved 4-5-fold knockdown for each gene using the following guides: 5′ -TTGGGGATCCCGGCCCGGAGCGCGTTTAAGAGC-3′ for PANX2 and 5′ -TTGGGCCTTATAAGCTGAGGGAGGTTTAAGAGC-3′ for NUPR1. We then performed lung colonization assays as described above.
Training and testing of oncRNA-based classifiers. Of the 201 oncRNAs, 100 were detected in at least one serum sample. We used these 100 oncRNAs to train a GBC on subtype-annotated TCGA-BRCA samples (sklearn module). We then bootstrapped our compendium of serum samples from 35 healthy controls 30 and 40 patients with cancer 100 times to calculate the performance parameters of the classifier, namely average AUROC, precision and accuracy scores. We also performed an independent assessment of oncRNAs by performing training and testing on the serum data as opposed to TCGA-BRCA (fivefold cross-validation).
We used the following miRNAs to perform similar analyses as above: miR-10b-5p, miR-10b-3p, miR-148b-3p, miR-148b-5p, miR-155-3p, miR-155-5p, miR-34a-3p, miR-376a-3p, miR-652-3p, miR-133a-3p, miR-139-3p, miR-143-3p, miR-145-3p, miR-15a-3p, miR-18a-3p, miR-425-3p, miR-34a-5p, miR-376a-5p, miR-652-5p, miR-133a-5p, miR-139-5p, miR-143-5p, miR-145-5p, miR-15a-5p, miR-18a-5p, miR-425-5p, miR-127-3p, miR-194-5p, miR-205-5p, miR-21-5p, miR-375, miR-376c-3p, miR-382-5p, miR-409-3p and miR-411-5p. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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Sample size
We have used power analysis based on a collection of control cells in xenografted mice to pick a cohort size >=4 for observing a >2-fold change in colonization.
Data exclusions Data was excluded in case of mortality unrelated to the experiment.
Replication
Experiments are performed in duplicates/triplicates and are often verified with accompanying qPCR analyses. Importantly, our analyses rely on regulon-level analysis and as such are not sensitive to noise associated with measurements of individual genes. Clinical associations were tested in multiple datasets and validated in independent cohorts.
Randomization Animals were mixed and regrouped before each experiment.
Blinding
Experiments were not blinded.
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The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
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Methodology
Sample preparation MDA-231 cells were obtained from ATCC. Cell monolayers were dissociated with 0.25% trypsin-EDTA and then resuspended in dPBS.
Instrument BD FACSAria II.
Software BD FACSDiva software was used for collecting the data. Analysis was done using the FCSparser package in python.
Cell population abundance Cells were classified into different cell cycle phases by manually setting thresholds on the Propidium Iodide histogram.
Thresholds attempted to maximize the area for each peak. Within each sample type, all replicates used the same thresholds.
Gating strategy N/A Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
